Pavan Cheruvu

Pavan Cheruvu, MD, currently serves as President and CEO of Bitterroot Bio and brings extensive leadership experience across the biotechnology and medical device sectors. Prior to joining Bitterroot, Dr. Cheruvu was an early member of the executive team at Roivant Sciences and served as President, CEO, and Chief R&D Officer at Sio Gene Therapies, a publicly traded company. Over the course of his career, he has held leadership roles at multiple biotechnology and medical device companies, with focus areas spanning neurology, oncology, and cardiovascular medicine. Dr. Cheruvu previously worked as a management consultant at McKinsey & Company, where he focused on M&A strategy and R&D transformation for biopharmaceutical firms across North America, Asia, and Europe.

Dr. Cheruvu holds a BS in biomedical engineering, electrical engineering, and chemistry from Duke University and an MSc in computer science from the University of Oxford, where he was a Rhodes Scholar. He went on to earn an MD from the Health, Sciences, and Technology (HST) program at Harvard Medical School and MIT. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training as a clinical fellow in cardiovascular medicine at the University of California, San Francisco.  

In addition, Dr. Cheruvu currently serves on the Executive Leadership Team of the American Heart Association Research Roundtable and the Board of Advisors of Life Sciences Cares Bay Area.